Mouse Models for the Study of Autoimmune Type 1 Diabetes: a NOD to Similarities and Differences to Human Disease

Overview

Journal Semin Immunopathol

Publisher Springer

Specialties Allergy & Immunology
Pathology

Date 2010 Apr 29

PMID 20424843

Citations 93

Authors

John P Driver

David V Serreze

Yi-Guang Chen

Affiliations

Soon will be listed here.

Abstract

For almost 30 years, the non-obese diabetic (NOD) mouse has served as the primary model for dissecting the genetic and pathogenic basis for T-lymphocyte-mediated autoimmune type 1 diabetes (T1D). However, while sharing many similarities, it is becoming increasingly appreciated that there are also some differences in the immunopathogenic basis of T1D development between humans and NOD mice. This review will focus on aspects of T1D development in NOD mice that are similar and different from that in humans.

Citing Articles

TCL1A in naïve B cells as a therapeutic target for type 1 diabetes.

Luo S, Zhang L, Wei C, Guo C, Meng Z, Zeng H EBioMedicine. 2025; 113:105593.

PMID: 39946833 PMC: 11872515. DOI: 10.1016/j.ebiom.2025.105593.

Tipping the balance in autoimmunity: are regulatory t cells the cause, the cure, or both?.

Hardtke-Wolenski M, Landwehr-Kenzel S Mol Cell Pediatr. 2024; 11(1):3.

PMID: 38507159 PMC: 10954601. DOI: 10.1186/s40348-024-00176-8.

Selective ablation of thymic and peripheral Foxp3 regulatory T cell development.

Yilmazer A, Zevla D, Malmkvist R, Rodriguez C, Undurraga P, Kirgin E Front Immunol. 2024; 14:1298938.

PMID: 38164128 PMC: 10757929. DOI: 10.3389/fimmu.2023.1298938.

Chimeric Antigen Receptor (CAR)-Based Cell Therapy for Type 1 Diabetes Mellitus (T1DM); Current Progress and Future Approaches.

Mohammadi V, Jahani Maleki A, Nazari M, Siahmansouri A, Moradi A, Elahi R Stem Cell Rev Rep. 2023; 20(3):585-600.

PMID: 38153634 DOI: 10.1007/s12015-023-10668-1.

Antidiabetic and Immunoregulatory Activities of Extract of L. in NOD with Spontaneous and Cyclophosphamide-Accelerated Diabetic Mice.

Lin C, Kuo Y, Shih C Int J Mol Sci. 2023; 24(12).

PMID: 37373070 PMC: 10298654. DOI: 10.3390/ijms24129922.

References

Hong S, Wilson M, Serizawa I, Wu L, Singh N, Naidenko O . The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med. 2001; 7(9):1052-6. DOI: 10.1038/nm0901-1052. View

Hammond K, Poulton L, Palmisano L, Silveira P, Godfrey D, Baxter A . alpha/beta-T cell receptor (TCR)+CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med. 1998; 187(7):1047-56. PMC: 2212199. DOI: 10.1084/jem.187.7.1047. View

Dendrou C, Plagnol V, Fung E, Yang J, Downes K, Cooper J . Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet. 2009; 41(9):1011-5. PMC: 2749506. DOI: 10.1038/ng.434. View

Krishnamurthy B, Dudek N, McKenzie M, Purcell A, Brooks A, Gellert S . Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. J Clin Invest. 2006; 116(12):3258-65. PMC: 1679712. DOI: 10.1172/JCI29602. View

Delovitch T, Singh B . The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity. 1998; 7(6):727-38. DOI: 10.1016/s1074-7613(00)80392-1. View

Rapoport M, Jaramillo A, Zipris D, Lazarus A, Serreze D, Leiter E . Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med. 1993; 178(1):87-99. PMC: 2191073. DOI: 10.1084/jem.178.1.87. View

Lee Y, Chin R, Christiansen P, Sun Y, Tumanov A, Wang J . Recruitment and activation of naive T cells in the islets by lymphotoxin beta receptor-dependent tertiary lymphoid structure. Immunity. 2006; 25(3):499-509. DOI: 10.1016/j.immuni.2006.06.016. View

Fiorina P, Vergani A, Dada S, Jurewicz M, Wong M, Law K . Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes. 2008; 57(11):3013-24. PMC: 2570398. DOI: 10.2337/db08-0420. View

Liston A, Lesage S, Gray D, OReilly L, Strasser A, Fahrer A . Generalized resistance to thymic deletion in the NOD mouse; a polygenic trait characterized by defective induction of Bim. Immunity. 2004; 21(6):817-30. DOI: 10.1016/j.immuni.2004.10.014. View

10.

Dai Y, Marrero I, Gros P, Zaghouani H, Wicker L, Sercarz E . Slc11a1 enhances the autoimmune diabetogenic T-cell response by altering processing and presentation of pancreatic islet antigens. Diabetes. 2008; 58(1):156-64. PMC: 2606865. DOI: 10.2337/db07-1608. View

11.

Dosch H, Cheung R, Karges W, Pietropaolo M, Becker D . Persistent T cell anergy in human type 1 diabetes. J Immunol. 1999; 163(12):6933-40. View

12.

Lenardo M . Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature. 1991; 353(6347):858-61. DOI: 10.1038/353858a0. View

13.

McGuire H, Vogelzang A, Hill N, Flodstrom-Tullberg M, Sprent J, King C . Loss of parity between IL-2 and IL-21 in the NOD Idd3 locus. Proc Natl Acad Sci U S A. 2009; 106(46):19438-43. PMC: 2780811. DOI: 10.1073/pnas.0903561106. View

14.

Silveira P, Johnson E, Chapman H, Bui T, Tisch R, Serreze D . The preferential ability of B lymphocytes to act as diabetogenic APC in NOD mice depends on expression of self-antigen-specific immunoglobulin receptors. Eur J Immunol. 2003; 32(12):3657-66. DOI: 10.1002/1521-4141(200212)32:12<3657::AID-IMMU3657>3.0.CO;2-E. View

15.

Rutella S, Bonanno G, Pierelli L, Mariotti A, Capoluongo E, Contemi A . Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-alpha. Eur J Immunol. 2004; 34(5):1291-302. DOI: 10.1002/eji.200324651. View

16.

Serreze D, Leiter E, Christianson G, Greiner D, Roopenian D . Major histocompatibility complex class I-deficient NOD-B2mnull mice are diabetes and insulitis resistant. Diabetes. 1994; 43(3):505-9. DOI: 10.2337/diab.43.3.505. View

17.

Serreze D, Gaskins H, Leiter E . Defects in the differentiation and function of antigen presenting cells in NOD/Lt mice. J Immunol. 1993; 150(6):2534-43. View

18.

Spolski R, Kashyap M, Robinson C, Yu Z, Leonard W . IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc Natl Acad Sci U S A. 2008; 105(37):14028-33. PMC: 2544573. DOI: 10.1073/pnas.0804358105. View

19.

Pillai A, George T, Dutt S, Strober S . Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. Blood. 2009; 113(18):4458-67. PMC: 2676099. DOI: 10.1182/blood-2008-06-165506. View

20.

Giordano C, Panto F, Caruso C, Modica M, Zambito A, Sapienza N . Interleukin 2 and soluble interleukin 2-receptor secretion defect in vitro in newly diagnosed type I diabetic patients. Diabetes. 1989; 38(3):310-5. DOI: 10.2337/diab.38.3.310. View